Loading…
iSpecimen Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ISPC.
▼ -100.0% over 5Y.
today you would have $0.27▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $10.40 | $106.20 | $400.80 | $1,100.00 | |
| P/S | 0.8x | 1.1x | 0.5x | 0.5x | 1.2x |
| P/B | 0.7x | 0.7x | 1.4x | 0.5x | 0.6x |
| EPS | -$91.20 | -$703.20 | -$982.00 | -$928.00 | |
| Profit margin | -123.16% | -543.68% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SPRCSciSparc Ltd. | $6.58 | 0.1x | 0.6x | — | -178.39% | $3.82M |
| VIVSVivoSim Labs, INC. | $0.29 | — | 0.2x | — | -343.10% | $3.82M |
| GOVXGeoVax Labs, Inc. | $0.72 | — | 3.0x | — | -891.59% | $3.76M |
| RDHLRedHill Biopharma Ltd. | $0.66 |
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
Company description provided by Yahoo Finance.
| -134.51% |
| -111.80% |
| -98.50% |
| ROE | -226.77% | -339.60% | -377.46% | -113.95% | -50.45% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.8x |
| — |
| — |
| $4.02M |
| MBIOMustang Bio Inc | $0.54 | — | 0.5x | — | -58.12% | $4.07M |
| TCRTAlaunos Therapeutics, Inc. | $1.61 | — | 3.0x | — | -185.95% | $4.08M |